These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Zebedee SL; Koduri RK; Mukherjee J; Mukherjee S; Lee S; Sauer DF; Scharff MD; Casadevall A Antimicrob Agents Chemother; 1994 Jul; 38(7):1507-14. PubMed ID: 7979280 [TBL] [Abstract][Full Text] [Related]
9. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943 [TBL] [Abstract][Full Text] [Related]
10. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi? Pirofski LA; Casadevall A Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968 [TBL] [Abstract][Full Text] [Related]
11. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. Rivera J; Casadevall A J Immunol; 2005 Jun; 174(12):8017-26. PubMed ID: 15944309 [TBL] [Abstract][Full Text] [Related]
12. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. Feldmesser M; Kress Y; Casadevall A J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844 [TBL] [Abstract][Full Text] [Related]
13. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Mukherjee J; Pirofski LA; Scharff MD; Casadevall A Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3636-40. PubMed ID: 8475112 [TBL] [Abstract][Full Text] [Related]
14. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody]. Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436 [TBL] [Abstract][Full Text] [Related]
15. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. Dromer F; Charreire J J Infect Dis; 1991 May; 163(5):1114-20. PubMed ID: 2019759 [TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. Taborda CP; Casadevall A J Immunol; 2001 Feb; 166(3):2100-7. PubMed ID: 11160261 [TBL] [Abstract][Full Text] [Related]
17. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Yuan RR; Spira G; Oh J; Paizi M; Casadevall A; Scharff MD Infect Immun; 1998 Mar; 66(3):1057-62. PubMed ID: 9488395 [TBL] [Abstract][Full Text] [Related]
18. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. Lendvai N; Qu XW; Hsueh W; Casadevall A J Immunol; 2000 Apr; 164(8):4367-74. PubMed ID: 10754337 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Maitta RW; Datta K; Pirofski LA Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457 [TBL] [Abstract][Full Text] [Related]
20. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Beenhouwer DO; Yoo EM; Lai CW; Rocha MA; Morrison SL Infect Immun; 2007 Mar; 75(3):1424-35. PubMed ID: 17220317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]